P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL

Authors: T. Facon, T. Plesner, S. Usmani, S. Kumar, N. Bahlis, C. Hulin, R. Orlowski, H. Nahi, P. Mollee, K. Ramasamy, M. Roussel, A. Jaccard, M. Delforge, L. Karlin, B. Arnulf, A. Chari, H. Pei, N. Gupta, S. Kaila, K. Matt, K. Gries, R. Carson, F. Borgsten, K. Weisel, A. Perrot

Published: 2023-11-16

DOI: 10.1097/01.hs9.0000936192.21618.f2

Source: Full article

---

Abstract

No abstract found.